Navigation Links
King and Pain Therapeutics Announce REMOXY(R) NDA Update
Date:7/7/2009

BRISTOL, Tenn. and SAN MATEO, Calif., July 7 /PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced that on July 2, 2009, King met with the US Food and Drug Administration (FDA) to discuss the Complete Response Letter regarding the New Drug Application (NDA) for REMOXY(R). The outcome of this meeting provided King with a clear path forward to resubmit the REMOXY(R) NDA and to address all FDA comments in the Complete Response Letter.

King now anticipates the resubmission of the NDA could occur mid-year 2010. The Company believes the rate-limiting step is the generation of six-month stability data, and no new clinical trials are required. King remains committed to the development and commercialization of REMOXY(R), and looks forward to working closely with the FDA toward approval of the product.

About REMOXY(R)

REMOXY, an investigational drug, is a unique, long-acting oxycodone formulation for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. In mid-2008, an NDA for REMOXY was accepted by the FDA and was granted Priority Review. In December 2008, Pain Therapeutics received a Complete Response Letter from the FDA. Subsequent to the receipt of the Complete Response Letter, King assumed full control of all activities related to the development of REMOXY(R).

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangement
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
2. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
3. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
4. PTC Therapeutics Receives $2.6 Million in Government Grants
5. Cell Therapeutics on Preliminary List of Additions to Russell 3000(R) Index and Russell Global(R) Index
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
8. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
9. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
10. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
11. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical Center ... became the first hospital on the West Coast to ... new surgical option provides women with a state-of-the-art, minimally ... Marc Winter , M.D., a highly regarded ... and medical director of minimally invasive surgery at Saddleback ...
(Date:5/23/2013)... Miami, FL (PRWEB) May 23, 2013 ... made trips to supermarkets to search for the ... grocery store aisles. Results from a year long study ... bacteria level in foods, specifically meats, over previous years. ... explains how the growth of antibiotic resistant bacteria in ...
(Date:5/23/2013)... The New Jersey chapter of the largest ... Associates (BDPA), is hosting its 10th annual Families in ... event will encourage students and their parents to explore ... from many of the industries’ finest teachers. Held from ... Institute of Technology, the event will include workshops, instruction ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 During ... is critical to adhere to principles of good ... , Esteemed speaker Dr. Jeremy Lim, Fellow, Clinical ... , ,     Understand the International Conference ... (GCP) and additional regulations for the conduction of ...
Breaking Biology Technology:Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... Amicus Therapeutics,(Nasdaq: FOLD ), a biopharmaceutical company ... of human,genetic diseases, will announce second quarter 2008 ... Thursday, August 7, 2008. The results,announcement will be ... that,afternoon at 5 p.m. EDT., Interested participants ...
... Industrial ... Contracted ... (Nasdaq:,PURE) today announced an agreement with DuraBan International Inc ... DuraClean(TM) brand., (Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO ), DuraBan ...
... MELVILLE, N.Y., July 31 Gentiva Health,Services, Inc. ... of,comprehensive home health services, today reported strong second ... and admissions,in the Company,s Home Health segment., ... the quarter ended June 29, 2008 included:, ...
Cached Biology Technology:Amicus Therapeutics Announces Second Quarter 2008 Results Release Date 2PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 2PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 3PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 4Gentiva Reports Strong Second Quarter led by Home Health Segment 2Gentiva Reports Strong Second Quarter led by Home Health Segment 3Gentiva Reports Strong Second Quarter led by Home Health Segment 4Gentiva Reports Strong Second Quarter led by Home Health Segment 5Gentiva Reports Strong Second Quarter led by Home Health Segment 6Gentiva Reports Strong Second Quarter led by Home Health Segment 7Gentiva Reports Strong Second Quarter led by Home Health Segment 8Gentiva Reports Strong Second Quarter led by Home Health Segment 9Gentiva Reports Strong Second Quarter led by Home Health Segment 10Gentiva Reports Strong Second Quarter led by Home Health Segment 11Gentiva Reports Strong Second Quarter led by Home Health Segment 12
(Date:5/22/2013)... (NLST) investigators also conclude that the 20 percent ... tomography (LDCT) versus chest X-ray (CXR) screening previously ... at experienced screening centers in the United States. ... with their patients about the benefits and risks ... in the New England Journal of Medicine ...
(Date:5/22/2013)... A new, streamlined approach to genetic engineering drastically ... new genes into bacteria, the workhorses of biotechnology, ... ACS Synthetic Biology , the method paves the ... for drug development, environmental cleanup and other activities. ... or integrating, a piece of the genetic material ...
(Date:5/22/2013)... 2013 Early screening for prostate cancer could become ... for women, thanks to UC Irvine research published today ... . , After more than a decade of work, ... identify clinically usable markers for prostate cancer in urine, ... with greater accuracy and at dramatically lower cost. The ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... solved the structure of a critical piece of synapse-associated protein ... where it is believed to play a role in everything ... The Journal of Biological Chemistry. , Dale Mierke, associate professor ... piece of SAP97 is built is an important step. Now ...
... Medical Center researchers have discovered a new ... the neurotransmitter dopamine exert their effects on ... of pleasure, excess concentrations of dopamine underlie ... psychiatric conditions. The findings therefore provide new ...
... but there's a recent wiki article with more details . ... A rat? A Guinea pig? Try none of the above. , ... long-whiskered rodent with stubby legs and a tail covered in dense ... it's actually more like a guinea pig or chinchilla. But not ...
Cached Biology News:Researchers reveal secret of key protein in brain and heart function 2Discovery of New Dopamine Action May Yield Alternative Psychiatric Drugs 2Discovery of New Dopamine Action May Yield Alternative Psychiatric Drugs 3Scientists discover odd-ball rodent 2
RABBIT ANTI SRC-RSV...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 9 ... tubes. Box dimensions: 13 x 13 x ...
RABBIT ANTI BACTERIAL HISTIDASE...
Biology Products: